12-27-04

B-

Certificate of Mailing:
The undersigned certifies that this correspondence
is being sent via Express Mail, postage prepaid,
in an envelope addressed to the Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450,
this 22nd day of December, 2004
(s) _____
Linda S. Evans

PRINTER'S RUSH

Express Mail Label No.: EV457833815US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Darrow et al.

Atty Docket: ORT-1560

Serial No.: 10/041,054

Art Unit: 1652

Filed: January 7, 2002

Examiner: William W. Moore

For: DNA Encoding The Human Serine Protease T

Confirmation No.: 3780

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Issue Branch

RESPONSE TO EXAMINER'S REQUEST FOR SUBSTITUTE SEQUENCE LISTING

Sir:

The accompanying substitute Sequence Listing is being filed in response to a request by Examiner Moore made in a telephonic message to the undersigned on December 10, 2004 regarding the above-captioned allowed application, which is being prepared for issuance (the issue fee having been transmitted on October 29, 2004). Examiner Moore informed the undersigned that the sequence information set forth in the computer readable form (CRF) did not correspond with the paper version of the Sequence Listing as filed with the present application on January 7, 2002. In particular,

the Examiner informed the undersigned that the paper version of the Sequence Listing as filed is apparently incomplete insofar as it contains only nine sequences, whereas the CRF contains two additional sequences, as reflected in the parent U.S. application, Serial No. 09/386,653, now U.S. Patent No. 6,458,564.

Upon review, it is apparent that the paper version of the Sequence Listing of record in the present divisional application indeed fails to include SEQ.ID.NO.:10 and SEQ.ID.NO.:11. The undersigned appreciates the USPTO's detection of this error.

To correct the error, which the undersigned believes was made in good faith without deceptive intent, Applicant is providing herewith a substitute Sequence Listing, which contains all eleven sequences. The addition of SEQ.ID.NO.:10 and SEQ.ID.NO.:11 in the accompanying substitute Sequence Listing is supported not only by the CRF as originally filed, but also by Table 1 of the specification, which provides the amino acid sequences corresponding to SEQ. ID. NO.: 10 and SEQ.ID.NO.: 11. Thus, the substitute Sequence Listing does not include new matter.

Pursuant to 37 C.F.R. §1.825(b), a diskette containing a substitute CRF is also enclosed. The undersigned states that the enclosed CRF is the same as the substitute Sequence Listing in paper form submitted herewith. Since the substitute Sequence Listing corrects the above-noted informalities and includes no new matter, Applicant respectfully requests its entry so that the patent issuing from this application will list complete sequence information.

It is believed that no fee is due in connection with the submission of this paper. If it is determined that any fee is due, however, please charge all necessary fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date: December 22, 2004

Linda S. Evans
Reg. No. 33,873

LSE/MDR

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406

SEQUENCE LISTING

<110> Darrow, Andrew
Qi, Jenson
Andrade-Gordon, Patricia

<120> DNA ENCODING THE HUMAN SERINE PROTEASE T

<130> ORT-1560

<140> 10/041,054
<141> 2002-01-07

<150> 09/386,653
<151> 1999-08-31

<160> 11

<170> PatentIn version 3.3

<210> 1
<211> 1110
<212> DNA
<213> Homo sapiens

<400> 1
gaccacggcc ctgcgcccca gccaggcctg aggacatgag gcggccggcg gcggtgccgc 60

tcctgctgct gctgtgtttt gggtctcaga gggccaaggc agcaacagcc tgtggtcgcc 120

ccaggatgct gaaccgaatg gtgggcgggc aggacacgca ggagggcgag tggccctggc 180

aagtcagcat ccagcgcaac ggaagccact tctgcggggg cagcctcatc gcggagcagt 240

gggtcctgac ggctgcgcac tgcttccgca acacctctga gacgtccctg taccaggtcc 300

tgctgggggc aaggcagcta gtgcagccgg gaccacacgc tatgtatgcc cgggtgaggc 360

aggtggagag caacccccctg taccagggca cggcctccag cgctgacgtg gccctggtgg 420

agctggaggc accagtgccc ttcaccaatt acatcctccc cgtgtgcctg cctgacccct 480

cggtgatctt tgagacgggc atgaactgct gggtcactgg ctggggcagc cccagtgagg 540

aagacctcct gcccgaaccg cggatcctgc agaaactcgc tgtgcccatc atcgacacac 600

ccaagtgcaa cctgctctac agcaaagaca ccgagtttgg ctaccaaccc aaaaccatca 660

agaatgacat gctgtgcgcc ggcttcgagg agggcaagaa ggatgcctgc aagggcgact 720

cgggcggccc cctggtgtgc ctcgtgggtc agtcgtggct gcaggcgggg gtgatcagct 780

ggggtgaggg ctgtgcccgc cagaaccgcc caggtgtcta catccgtgtc accgcccacc 840

acaactggat ccatcggatc atccccaaac tgcagttcca gccagcgagg ttgggcggcc 900

agaagtgaga ccccggggc caggagcccc ttgagcagag ctctgcaccc agcctgcccg 960

cccacaccat cctgctggtc ctcccagcgc tgctgttgca cctgtgagcc ccaccagact 1020

catttgtaaa tagcgctcct tcctcccctc tcaaataccc ttattttatt tatgtttctc 1080

ccaataaaaa cccagcctgt gtgccagctg 1110

<210> 2
<211> 20
<212> DNA
<213> Artificial

<220>
<223> ProtT PCRTP-U PCR primer

<400> 2
gccaggcctg aggacatgag 20

<210> 3
<211> 20
<212> DNA
<213> Artificial

<220>
<223> ProtT PCRTP-L PCR primer

<400> 3
tgcgctggat gctgacttgc 20

<210> 4
<211> 40
<212> DNA

<213> Artificial

<220>
<223> ProtT PCTTP-PP primer

<400> 4
ccaggatgct gaaccgaatg gtgggcgggc aggacacgca 40

<210> 5
<211> 30
<212> DNA
<213> Artificial

<220>
<223> ProtT Xba-U PCR prmer

<400> 5
aggatctaga ggagggcgag tggccctggc 30

<210> 6
<211> 30
<212> DNA
<213> Artificial

<220>
<223> ProtT Xba-L PCR primer

<400> 6
ggggtctaga cttctggccg cccaacctcg 30

<210> 7
<211> 290
<212> PRT
<213> Homo sapiens

<400> 7

Met Arg Arg Pro Ala Ala Val Pro Leu Leu Leu Leu Leu Cys Phe Gly
1 5 10 15

Ser Gln Arg Ala Lys Ala Ala Thr Ala Cys Gly Arg Pro Arg Met Leu
20 25 30

Asn Arg Met Val Gly Gly Gln Asp Thr Gln Glu Gly Glu Trp Pro Trp
35 40 45

Gln Val Ser Ile Gln Arg Asn Gly Ser His Phe Cys Gly Gly Ser Leu
50 55 60

Ile Ala Glu Gln Trp Val Leu Thr Ala Ala His Cys Phe Arg Asn Thr
65 70 75 80

Ser Glu Thr Ser Leu Tyr Gln Val Leu Leu Gly Ala Arg Gln Leu Val
85 90 95

Gln Pro Gly Pro His Ala Met Tyr Ala Arg Val Arg Gln Val Glu Ser
100 105 110

Asn Pro Leu Tyr Gln Gly Thr Ala Ser Ser Ala Asp Val Ala Leu Val
115 120 125

Glu Leu Glu Ala Pro Val Pro Phe Thr Asn Tyr Ile Leu Pro Val Cys
130 135 140

Leu Pro Asp Pro Ser Val Ile Phe Glu Thr Gly Met Asn Cys Trp Val
145 150 155 160

Thr Gly Trp Gly Ser Pro Ser Glu Glu Asp Leu Leu Pro Glu Pro Arg
165 170 175

Ile Leu Gln Lys Leu Ala Val Pro Ile Ile Asp Thr Pro Lys Cys Asn
180 185 190

Leu Leu Tyr Ser Lys Asp Thr Glu Phe Gly Tyr Gln Pro Lys Thr Ile
195 200 205

Lys Asn Asp Met Leu Cys Ala Gly Phe Glu Glu Gly Lys Lys Asp Ala
210 215 220

Cys Lys Gly Asp Ser Gly Gly Pro Leu Val Cys Leu Val Gly Gln Ser
225 230 235 240

Trp Leu Gln Ala Gly Val Ile Ser Trp Gly Glu Gly Cys Ala Arg Gln
245 250 255

Asn Arg Pro Gly Val Tyr Ile Arg Val Thr Ala His His Asn Trp Ile
260 265 270

His Arg Ile Ile Pro Lys Leu Gln Phe Gln Pro Ala Arg Leu Gly Gly
275 280 285

Gln Lys
290

<210> 8
<211> 1130
<212> DNA
<213> Artificial

<220>
<223> PFEK-PROTT-HIS fusion protein nucleic acid sequence

<400> 8
gaattcacca ccatggacag caaaggttcg tcgcagaaat cccgcctgct cctgctgctg 60

gtggtgtcaa atctactctt gtgccagggt gtggtctccg actacaagga cgacgacgac 120

gtggacgcgg ccgctcttgc tgccccctttt gatgatgatg acaagatcgt tgggggctat 180

gctctagagg agggcgagtg gccctggcaa gtcagcatcc agcgcaacgg aagccacttc 240

tgcgggggca gcctcatcgc ggagcagtgg gtcctgacgg ctgcgcactg cttccgcaac 300

acctctgaga cgtccctgta ccaggtcctg ctgggggcaa ggcagctagt gcagccggga 360

ccacacgcta tgtatgcccg ggtgaggcag gtggagagca acccccctgta ccagggcacg 420

gcctccagcg ctgacgtggc cctggtggag ctggaggcac cagtgccctt caccaattac 480

atcctccccg tgtgcctgcc tgacccctcg gtgatctttg agacgggcat gaactgctgg 540

gtcactggct ggggcagccc cagtgaggaa gacctcctgc ccgaaccgcg gatcctgcag 600

aaactcgctg tgcccatcat cgacacaccc aagtgcaacc tgctctacag caaagacacc 660

gagtttggct accaacccaa aaccatcaag aatgacatgc tgtgcgccgg cttcgaggag 720

ggcaagaagg atgcctgcaa gggcgactcg ggcggccccc tggtgtgcct cgtgggtcag 780

tcgtggctgc aggcgggggt gatcagctgg ggtgagggct gtgcccgcca gaaccgccca 840

ggtgtctaca tccgtgtcac cgcccaccac aactggatcc atcggatcat ccccaaactg 900

cagttccagc cagcgaggtt gggcggccag aagtctagac atcaccatca ccatcactag 960

cggccgcttc cctttagtga gggttaatgc ttcgagcaga catgataaga tacattgatg 1020

agtttggaca aaccacaact agaatgcagt gaaaaaaatg ctttatttgt gaaatttgtg 1080

atgctattgc tttatttgta accattataa gctgcaataa acaagttgac 1130

<210> 9
<211> 315
<212> PRT
<213> Artificial

<220>
<223> PFEK-PROTT-HIS fusion protein amino acid sequence

<400> 9

Met Asp Ser Lys Gly Ser Ser Gln Lys Ser Arg Leu Leu Leu Leu Leu
1 5 10 15

Val Val Ser Asn Leu Leu Leu Cys Gln Gly Val Val Ser Asp Tyr Lys
20 25 30

Asp Asp Asp Asp Val Asp Ala Ala Ala Leu Ala Ala Pro Phe Asp Asp
35 40 45

Asp Asp Lys Ile Val Gly Gly Tyr Ala Leu Glu Glu Gly Glu Trp Pro
50 55 60

Trp Gln Val Ser Ile Gln Arg Asn Gly Ser His Phe Cys Gly Gly Ser
65 70 75 80

Leu Ile Ala Glu Gln Trp Val Leu Thr Ala Ala His Cys Phe Arg Asn
85 90 95

Thr Ser Glu Thr Ser Leu Tyr Gln Val Leu Leu Gly Ala Arg Gln Leu
100 105 110

Val Gln Pro Gly Pro His Ala Met Tyr Ala Arg Val Arg Gln Val Glu
115 120 125

Ser Asn Pro Leu Tyr Gln Gly Thr Ala Ser Ser Ala Asp Val Ala Leu
130 135 140

Val Glu Leu Glu Ala Pro Val Pro Phe Thr Asn Tyr Ile Leu Pro Val
145 150 155 160

Cys Leu Pro Asp Pro Ser Val Ile Phe Glu Thr Gly Met Asn Cys Trp
165 170 175

Val Thr Gly Trp Gly Ser Pro Ser Glu Glu Asp Leu Leu Pro Glu Pro
180 185 190

Arg Ile Leu Gln Lys Leu Ala Val Pro Ile Ile Asp Thr Pro Lys Cys
195 200 205

Asn Leu Leu Tyr Ser Lys Asp Thr Glu Phe Gly Tyr Gln Pro Lys Thr
210 215 220

Ile Lys Asn Asp Met Leu Cys Ala Gly Phe Glu Glu Gly Lys Lys Asp
225 230 235 240

Ala Cys Lys Gly Asp Ser Gly Gly Pro Leu Val Cys Leu Val Gly Gln
245 250 255

Ser Trp Leu Gln Ala Gly Val Ile Ser Trp Gly Glu Gly Cys Ala Arg
260 265 270

Gln Asn Arg Pro Gly Val Tyr Ile Arg Val Thr Ala His His Asn Trp
275 280 285

Ile His Arg Ile Ile Pro Lys Leu Gln Phe Gln Pro Ala Arg Leu Gly
290 295 300

Gly Gln Lys Ser Arg His His His His His His
305 310 315

<210> 10
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Chromogenic substrate 5

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-Succinyl-alanine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Phe-p-nitroanilide

<400> 10

Xaa Ala Pro Xaa

1

<210> 11
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Chromogenic substrate 6

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-(methoxysuccinyl)-Ala

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Val-p-nitroanilide

<400> 11

Xaa Ala Pro Xaa
1